Full Coverage

Gilead Sciences' lenacapavir receives FDA approval for HIV prevention

Posts on X

Formerly Twitter
Gilead Sciences
GileadSciences
Congratulations to Gilead’s Tomas Cihlar who received the 2025 Warren Alpert Foundation Prize for his scientific leadership in the development of a novel HIV medication that has the potential to change the landscape in HIV prevention and treatment. pic.x.com/awblsm27Fp
Posted on X
Gilead Sciences
GileadSciences
#InTheNews: Earlier today, we received FDA approval for our #HIV prevention medication. Read more on this milestone moment in our mission to help end the HIV epidemic: gilead.inc/4eaEiUO pic.x.com/PJeUDLm1H0
Posted on X
UNAIDS Global
UNAIDS
✍️@Guardian | Lenacapavir, twice-yearly HIV prevention injection could cost just $25 per patient a year, say researchers—yet may be priced at 1000x more. This medicine could help end the HIV pandemic. We urge @GileadSciences: Do the right thing. Make it affordable. Save lives.
Posted on X
Unitaid
UNITAID
We’ve seen what’s possible when access is prioritized. Let’s ensure lenacapavir delivers impact, not just headlines. Thanks to @NPR's @evolambert for reporting on both the scientific breakthrough and the equity challenge. Learn more: www.npr.org/sections/goats-and-soda/2025/06/18/g-s1-73130/hiv-prevention-drug-lenacapavir-fda-breakthrough
Posted on X

All coverage

HomeFollowing
Search
Clear search
Close search
Google apps
Main menu